C.R. Bard, Inc. (NYSE:BCR) VP John A. Deford sold 5,816 shares of the business’s stock in a transaction dated Thursday, February 9th. The shares were sold at an average price of $239.58, for a total value of $1,393,397.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
John A. Deford also recently made the following trade(s):
- On Monday, February 13th, John A. Deford sold 469 shares of C.R. Bard stock. The stock was sold at an average price of $240.07, for a total value of $112,592.83.
- On Monday, December 12th, John A. Deford sold 15,883 shares of C.R. Bard stock. The stock was sold at an average price of $218.03, for a total value of $3,462,970.49.
Shares of C.R. Bard, Inc. (NYSE:BCR) opened at 240.66 on Wednesday. C.R. Bard, Inc. has a 52 week low of $185.72 and a 52 week high of $241.50. The stock’s 50 day moving average is $233.09 and its 200-day moving average is $222.43. The stock has a market capitalization of $17.69 billion, a price-to-earnings ratio of 34.23 and a beta of 0.63.
C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Thursday, January 26th. The company reported $2.77 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.03. The firm had revenue of $967.10 million for the quarter, compared to analyst estimates of $956.12 million. C.R. Bard had a net margin of 14.31% and a return on equity of 48.48%. C.R. Bard’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period last year, the company posted $2.43 EPS. On average, analysts anticipate that C.R. Bard, Inc. will post $11.64 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, February 3rd. Shareholders of record on Monday, January 23rd were issued a dividend of $0.26 per share. The ex-dividend date was Thursday, January 19th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.43%. C.R. Bard’s payout ratio is currently 14.77%.
“Insider Selling: C.R. Bard, Inc. (BCR) VP Sells $1,393,397.28 in Stock” was reported by sleekmoney and is owned by of sleekmoney. If you are reading this news story on another domain, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be viewed at http://sleekmoney.com/insider-selling-c-r-bard-inc-bcr-vp-sells-1393397-28-in-stock/1661991.html.
Institutional investors have recently made changes to their positions in the stock. Whittier Trust Co. of Nevada Inc. boosted its stake in shares of C.R. Bard by 43.7% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 454 shares of the company’s stock valued at $107,000 after buying an additional 138 shares during the last quarter. Nicolet Bankshares Inc. raised its position in shares of C.R. Bard by 3.5% in the second quarter. Nicolet Bankshares Inc. now owns 1,416 shares of the company’s stock worth $333,000 after buying an additional 48 shares during the last quarter. BP PLC raised its position in shares of C.R. Bard by 66.7% in the second quarter. BP PLC now owns 15,000 shares of the company’s stock worth $3,527,000 after buying an additional 6,000 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH acquired a new stake in shares of C.R. Bard during the second quarter valued at about $12,496,000. Finally, Tocqueville Asset Management L.P. boosted its stake in shares of C.R. Bard by 1.8% in the second quarter. Tocqueville Asset Management L.P. now owns 7,072 shares of the company’s stock valued at $1,663,000 after buying an additional 124 shares during the period. 86.89% of the stock is owned by institutional investors and hedge funds.
BCR has been the subject of a number of research reports. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $267.00 target price for the company in a research report on Tuesday, January 31st. JMP Securities increased their price objective on shares of C.R. Bard from $240.00 to $255.00 in a report on Friday, January 27th. Needham & Company LLC reissued a “hold” rating on shares of C.R. Bard in a report on Friday, January 27th. BMO Capital Markets restated a “buy” rating on shares of C.R. Bard in a research report on Friday, January 27th. Finally, Raymond James Financial, Inc. raised C.R. Bard from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $250.00 to $265.00 in a report on Thursday, January 5th. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $244.14.
About C.R. Bard
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/insider-selling-c-r-bard-inc-bcr-vp-sells-1393397-28-in-stock/1661991.html
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.